当前位置: X-MOL 学术Front. Genet. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Six-lncRNA Immune Prognostic Signature for Cervical Cancer
Frontiers in Genetics ( IF 2.8 ) Pub Date : 2020-09-21 , DOI: 10.3389/fgene.2020.533628
Qian Chen 1 , Lang Hu 2 , Dongping Huang 3 , Kaihua Chen 4 , Xiaoqiang Qiu 5 , Bingqing Qiu 6
Affiliation  

Background

This study searched for immune-related long noncoding RNAs (lncRNAs) to predict the prognosis of patients with cervical cancer.

Method

We obtained immunologically relevant lncRNA expression profiles and clinical follow-up data from cervical cancer patients from The Cancer Genome Atlas database and the Molecular Signatures Database. Cervical cancer patients were randomly divided into a training group, testing group and combined group. The immune prognostic signature was constructed by Least Absolute Shrinkage and Selection Operator Cox regression, prognosis was analyzed by Kaplan–Meier curves between different groups, and the accuracy of the prognostic model was assessed by receiver operating characteristic-area under the curve (ROC-AUC) analysis.

Results

A six-lncRNA immune prognostic signature (LIPS) was constructed to predict the prognosis of cervical cancer. The six lncRNAs are as follows: AC009065.8, LINC01871, MIR210HG, GEMIN7-AS1, GAS5-AS1, and DLEU1. A ROC-AUC analysis indicated that the model could predict the prognosis of cervical cancer patients in different subgroups. A Kaplan–Meier analysis showed that patients with high risk scores had a poor prognosis; these results were equally meaningful in the subgroup analyses. Risk scores differed depending on the clinical pathology and tumor grade and were independent risk factors for cervical cancer prognosis. Gene set enrichment analysis revealed an association between the LIPS and the immune response, Wnt signaling pathway, and TGF beta signaling pathway.

Conclusion

Our study shows that the six-LIPS can predict the prognosis of cervical cancer and contribute to decisions regarding the immunotherapeutic strategy.



中文翻译:

宫颈癌的 6-lncRNA 免疫预后特征

Background

本研究寻找与免疫相关的长链非编码 RNA (lncRNA) 来预测宫颈癌患者的预后。

Method

我们从癌症基因组图谱数据库和分子特征数据库中获得了宫颈癌患者的免疫学相关 lncRNA 表达谱和临床随访数据。宫颈癌患者随机分为训练组、测试组和联合组。通过最小绝对收缩和选择算子 Cox 回归构建免疫预后特征,通过不同组间的 Kaplan-Meier 曲线分析预后,通过受试者工作特征曲线下面积(ROC-AUC)评估预后模型的准确性) 分析。

Results

构建了六种lncRNA免疫预后特征(LIPS)来预测宫颈癌的预后。六个lncRNA如下:AC009065.8、LINC01871、MIR210HG、GEMIN7-AS1、GAS5-AS1和DLEU1。ROC-AUC分析表明,该模型可以预测不同亚组宫颈癌患者的预后。Kaplan-Meier 分析显示,风险评分高的患者预后较差;这些结果在亚组分析中同样有意义。风险评分因临床病理和肿瘤分级而异,是宫颈癌预后的独立危险因素。基因集富集分析揭示了 LIPS 与免疫反应、Wnt 信号通路和 TGF β 信号通路之间的关联。

Conclusion

我们的研究表明,6-LIPS 可以预测宫颈癌的预后,并有助于决定免疫治疗策略。

更新日期:2020-10-15
down
wechat
bug